Fat-dissolving injection marketing: approved use, off-label and compounded

Fat-dissolving injections are on many med spa and aesthetic practice menus: “double chin injections,” “lipo dissolve,” “fat-melting shots” for the belly, arms, bra line or knees. One injectable prescription drug has FDA approval for this kind of treatment, and only for fat under the chin. Other areas are off-label uses of that drug, and many “lipolysis” or “mesotherapy” mixes are compounded or imported products that FDA has never approved for fat removal. The ad has to fit the product actually in the syringe.

This guide covers what FDA approved, how to talk about off-label areas, what FDA has said about compounded and unapproved fat-loss injections, and how results, risks, photos and prices fit under the FTC Act. For device-based fat reduction, see our guide to body contouring clinic marketing, and for cellulite treatments, our guide to cellulite treatment marketing. For who may compound and for whom, see our guide to compounding pharmacy marketing.

The short version

• One approved use. Drugs@FDA lists one new drug application for an injectable fat-reducing drug, approved April 29, 2015, and a generic version approved April 2, 2021. The labeling indicates it for “improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults,” which is fat under the chin.
• Other areas are not established. The same labeling says safe and effective use for fat outside the submental region “has not been established and is not recommended.” Jowls, belly, arms and bra-line fat are off-label for that drug.
• “Lipodissolve” mixes are not approved for fat removal. In 2010, FDA warned six U.S. companies over lipodissolve claims and said it was not aware of any credible scientific evidence that the injected substances eliminate fat.
• Results and risks follow FTC rules. Claims about how much fat goes away, how many sessions it takes, and how safe it is need evidence (15 USC 45, 52; FTC guidance). Leaving out material risks can make an ad misleading (15 USC 55(a)(1)).

What FDA approved

Drugs@FDA, read through openFDA on November 1, 2026, lists two applications for the active ingredient used in the approved product: the original new drug application, approved April 29, 2015 as a new molecular entity, and an abbreviated application for a generic version, approved April 2, 2021. Both are prescription products given by subcutaneous injection.

The prescribing information in openFDA (effective October 30, 2024) describes a cytolytic drug, meaning it destroys cells, and gives one indication: improving the appearance of moderate to severe fullness from fat under the chin in adults. It then sets a limitation of use: “The safe and effective use … for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.” The labeling also says the drug should be given by a healthcare professional, and that patients should be screened for other causes of fullness under the chin, such as an enlarged thyroid or swollen lymph nodes.

So an ad for “FDA-approved double chin injections” is accurate only if you use the approved drug, under the chin, in adults. The same drug in the jowls or abdomen is a use FDA has not approved, and a compounded or imported mix is not an FDA-approved drug for any of these uses.

Off-label areas

FDA’s page on unapproved uses says that once FDA approves a drug, healthcare providers generally may prescribe it for an unapproved use when they judge that it is medically appropriate for their patient. Prescribing is not the same as advertising. FDA’s rule on prescription drug advertisements bars a manufacturer’s ad from recommending or suggesting any use that is not in the approved labeling (21 CFR 202.1(e)(4)(i)(a)). That duty is written for the manufacturer, packer or distributor (21 USC 352(n)), and we found no FDA rule that applies it to a practice’s own service ads as such. Our guide to prescription treatment advertising covers that split in more detail.

The FTC test applies either way. An ad that presents an off-label area as approved, established or proven, without evidence of that strength, risks being misleading. For a practice that offers other areas:

• Do not attach “FDA-approved” to any area except fat under the chin.
• If you offer other areas, say plainly that FDA has not approved the drug for that area, and describe your evidence honestly. The labeling’s own words are that use outside the chin area “has not been established and is not recommended.”
• Do not use photos or results from chin treatments to sell other areas.
• Have counsel and your medical director review any page that promotes an off-label area before it runs.

Compounded and imported “lipodissolve” mixes

FDA’s April 7, 2010 news release described lipodissolve as a series of drug injections intended to dissolve and remove small pockets of fat, also called mesotherapy, lipozap, lipotherapy or injection lipolysis. It said the most commonly injected products were combinations of two drugs, sometimes mixed with vitamins, minerals or herbal extracts. FDA said it was “not aware of any credible scientific evidence that supports the effectiveness of any of these substances for fat elimination, and their safety when used alone or in combination is unknown.”

The release said FDA sent warning letters to six U.S. companies, med spas among them, and to a foreign online seller, and that the companies had been cited for claims including an outstanding safety record, superiority to liposuction, and treatment of conditions such as male breast enlargement and lipomas. FDA said it was not aware of clinical evidence for those claims, and that it had received reports of permanent scarring, skin deformation and deep painful knots where the products were injected. That release is from 2010 and is no longer posted on fda.gov; we read the archived copy. Since then, one drug has been approved for fat under the chin, but that approval does not extend to compounded mixtures.

Compounded drugs are exempt from FDA approval requirements only under the conditions in 21 USC 353a, including compounding for an identified individual patient based on a valid prescription, and not compounding regularly or in inordinate amounts drug products that are essentially copies of a commercially available drug product. FDA’s page on promoting compounded drugs (content current as of June 15, 2026) lists claims it considers false or misleading, including:

• describing a compounded drug as a generic version of an FDA-approved drug or the same as a drug FDA approved;
• claiming a compounded drug has been FDA-approved or otherwise evaluated for safety and effectiveness;
• describing a compounded drug as clinically proven to produce the same result as the FDA-approved drug;
• claiming a compounded drug comes from an FDA-approved or FDA-licensed pharmacy or outsourcing facility, because FDA does not approve or license any facility.

For fat-dissolving injections, that rules out “the same as the FDA-approved double chin injection, for less,” “FDA-approved lipo dissolve” and “from an FDA-approved pharmacy” for a compounded product. The compounding guide has the 503A and 503B details.

“Lipo” shots that do not dissolve fat

Some menus use “lipo” for vitamin or amino acid injections sold for weight loss or energy. Those are a different product from the injections above. If you call them “fat-burning” or “fat-dissolving,” that is a health claim that needs competent and reliable scientific evidence under the FTC guidance, for the specific product, dose and claim. Our IV therapy clinic marketing guide has a section on vitamin injection bars, and our weight loss clinic marketing guide covers weight claims.

Results, sessions and risks

The FTC Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that a marketer is responsible for implied claims as well as express ones. For fat-dissolving injections:

• Permanence. “Permanent fat removal” or “fat cells gone forever” is an objective claim. You need evidence for it, for your product and area.
• Sessions. The labeling allows up to 6 treatments at least 1 month apart. “One and done” or “results in one session” implies a typical outcome you would need evidence for.
• Comparison with surgery. “Liposuction without surgery” compares results with liposuction. Superiority to liposuction was one of the claims cited in the 2010 warning letters.
• Risks and downtime. The labeling’s warnings include marginal mandibular nerve injury (an asymmetric smile or facial muscle weakness), difficulty swallowing, bruising, hair loss at the injection site, and skin ulceration and necrosis, and its trials reported swelling, bruising, pain and numbness as common. “No downtime,” “no side effects” and “completely safe” do not fit. Under 15 USC 55(a)(1), whether an ad misleads includes what it fails to reveal about the consequences of use.
• Who it suits. The labeling asks clinicians to screen for other causes of fullness and to consider skin laxity. Do not imply that everyone with a double chin is a candidate.

Before and after photos

Under 16 CFR 255.2(a), an advertiser needs substantiation for what consumer endorsements convey, as if it had made the claim itself. Under 16 CFR 255.2(b), an endorsement about a central attribute is likely to be read as representative of what patients generally achieve, unless the ad clearly and conspicuously discloses the generally expected result. Swelling after treatment can change how the area looks for some time, so show when each photo was taken and how many sessions came before it, keep lighting, angle and head position the same, do not retouch, get written permission, and say that results vary. Only show the product and area the ad is about. Our guide to patient testimonials and before-and-after photos covers consent and privacy.

Prices and packages

Pricing is often per vial, per session or per package. Say which, and that the number of vials and sessions depends on the assessment, so a “$600 double chin treatment” headline does not become a different price at the chair. A “was $1,800, now $1,200” offer needs a former price you actually offered in good faith for a reasonably substantial period of time (16 CFR 233.1(a)). See our guide to was and now price claims.

An example (made up)

This illustration is invented to show how the rules fit together. A med spa posts: “FDA-approved lipo dissolve for your belly, arms and double chin! Melts fat forever in one session, no downtime. Same results as the brand-name shot for half the price. $299, was $800.” The med spa uses a compounded mixture for the belly and arms and the approved drug for the chin.

Fixes: “FDA-approved” can describe only the approved drug for fat under the chin. The belly and arm treatment uses a compounded product that FDA has not approved, so it cannot be called FDA-approved, “the same” as the approved drug, or a cheaper version of it. If the med spa keeps offering it, the page says so plainly, and counsel reviews it. “Forever” and “one session” go unless the med spa has evidence, “no downtime” becomes a line about swelling, bruising and other effects reviewed at consultation, the price says per vial or per session, and the $800 former price stays only if patients actually paid it.

Checklist

• You know which product is used for each area: the approved drug, or a compounded or imported product.
• “FDA-approved” appears only with the approved drug for fat under the chin in adults (Drugs@FDA; labeling).
• Off-label areas are labeled as not FDA approved for that area, with honest evidence and counsel review.
• Compounded products are never called FDA-approved, generic, the same as or clinically proven equal to the approved drug, or from an FDA-approved pharmacy (FDA, June 15, 2026).
• No permanence, one-session, liposuction comparison or safety claims without evidence (15 USC 45, 52; FTC guidance).
• Risks and downtime are mentioned, with a consultation step (15 USC 55(a)(1)).
• Before and after photos are real, consented, unretouched, timed and labeled with typical results (16 CFR 255.2).
• Prices say per vial, session or package; former prices were real (16 CFR 233.1).
• Who may inject, and under what supervision, checked against your state’s rules.

How we help

We build service pages and campaigns for med spas and aesthetic practices with drug status and claims checked against the sources above: website design, healthcare SEO for treatment searches, and lead generation campaigns. We do not give legal opinions on drug status or scope of practice, and we are not a law firm. For other injectables, see our guides to dermal filler advertising rules and neuromodulator advertising.

Sources

• FDA: Drugs@FDA database
• openFDA Drugs@FDA data (last updated October 30, 2026)
• openFDA drug labeling data (label effective October 30, 2024)
• FDA: FDA Issues Warning Letters for Drugs Promoted in Fat Elimination Procedure (April 7, 2010, archived copy)
• FDA: What to Know When Promoting Compounded Drugs (content current as of June 15, 2026)
• FDA: Understanding Unapproved Use of Approved Drugs “Off Label” (content current as of February 5, 2018)
• 21 CFR 202.1: Prescription-drug advertisements
• 21 USC 352: Misbranded drugs and devices
• 21 USC 353a: Pharmacy compounding
• 15 USC 45: Unfair methods of competition unlawful
• 15 USC 52: Dissemination of false advertisements
• 15 USC 55: Additional definitions
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 255.2: Consumer endorsements
• 16 CFR 233.1: Former price comparisons

More in Cash-pay, aesthetic and wellness care